Literature DB >> 27134682

Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis.

Alexis Ogdie1, Lihi Eder2.   

Abstract

Numerous studies have suggested a link between psoriatic arthritis (PsA) and comorbidities, in particular cardiovascular disease and metabolic comorbidities such as diabetes. The co-existence of these comorbidities is likely the result of systemic inflammation. In order to improve the health of patients with PsA and provide optimal care, these comorbidities must be addressed. However, little is known about how to improve metabolic and cardiovascular health in patients with PsA. In this perspective, we describe the research needs in the area of improving cardiovascular disease and metabolic comorbidities among patients with PsA.

Entities:  

Keywords:  cardiovascular disease; diabetes; metabolic disease; obesity; psoriatic arthritis; research

Year:  2015        PMID： 27134682      PMCID： PMC4847747          DOI： 10.2217/ijr.15.45

Source DB:  PubMed          Journal:  Int J Clin Rheumtol        ISSN： 1758-4280


  62 in total

1.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.

Authors:  M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2009-09-22       Impact factor: 19.103

2.  Framingham Risk Score underestimates cardiovascular disease risk in severe psoriatic patients: implications in cardiovascular risk factors management and primary prevention of cardiovascular disease.

Authors:  Tiago Torres; Rita Sales; Carlos Vasconcelos; Berta Martins da Silva; Manuela Selores
Journal:  J Dermatol       Date:  2013-10-16       Impact factor: 4.005

3.  Tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis, psoriatic arthritis, or both.

Authors:  Jashin J Wu; Kwun-Yee T Poon
Journal:  J Drugs Dermatol       Date:  2014-08       Impact factor: 2.114

4.  Disease severity and therapy as predictors of cardiovascular risk in psoriasis: a population-based cohort study.

Authors:  H Maradit-Kremers; M Icen; F C Ernste; R A Dierkhising; M T McEvoy
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-03       Impact factor: 6.166

5.  Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis.

Authors:  Cynthia S Crowson; Eric L Matteson; Veronique L Roger; Terry M Therneau; Sherine E Gabriel
Journal:  Am J Cardiol       Date:  2012-04-20       Impact factor: 2.778

Review 6.  Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?

Authors:  Paul M Ridker
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

7.  More americans living longer with cardiovascular disease will increase costs while lowering quality of life.

Authors:  Ankur Pandya; Thomas A Gaziano; Milton C Weinstein; David Cutler
Journal:  Health Aff (Millwood)       Date:  2013-10       Impact factor: 6.301

8.  Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis.

Authors:  Yih Chang Lin; Deepan Dalal; Sarah Churton; Danielle M Brennan; Neil J Korman; Esther S H Kim; M Elaine Husni
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-01       Impact factor: 4.794

9.  Psoriasis severity and the prevalence of major medical comorbidity: a population-based study.

Authors:  Howa Yeung; Junko Takeshita; Nehal N Mehta; Stephen E Kimmel; Alexis Ogdie; David J Margolis; Daniel B Shin; Rosemary Attor; Andrea B Troxel; Joel M Gelfand
Journal:  JAMA Dermatol       Date:  2013-10       Impact factor: 10.282

10.  Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis.

Authors:  Lihi Eder; Arane Thavaneswaran; Vinod Chandran; Richard Cook; Dafna D Gladman
Journal:  Ann Rheum Dis       Date:  2014-05-14       Impact factor: 19.103
View more
  5 in total

Review 1.  The Changing Face of Clinical Trials in Psoriatic Arthritis.

Authors:  Alexis Ogdie; Laura Coates
Journal:  Curr Rheumatol Rep       Date:  2017-04       Impact factor: 4.592

2.  Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study.

Authors:  Lihi Eder; Paula Harvey; Vinod Chandran; Cheryl F Rosen; Jan Dutz; James T Elder; Proton Rahman; Christopher T Ritchlin; Sherry Rohekar; Richard Hayday; Snezana Barac; Joy Feld; Devy Zisman; Dafna D Gladman
Journal:  J Rheumatol       Date:  2018-02-01       Impact factor: 4.666

3.  Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry.

Authors:  Arthur Kavanaugh; Kim Papp; Alice B Gottlieb; Elke M G J de Jong; Soumya D Chakravarty; Shelly Kafka; Wayne Langholff; Kamyar Farahi; Bhaskar Srivastava; Jose U Scher
Journal:  BMC Rheumatol       Date:  2018-09-29

Review 4.  Psoriatic arthritis and the association with cardiometabolic disease: a narrative review.

Authors:  Paras Karmacharya; Alexis Ogdie; Lihi Eder
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-03-02       Impact factor: 5.346

5.  Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis.

Authors:  Jon T Giles; Alexis Ogdie; Juan J Gomez Reino; Philip Helliwell; Rebecca Germino; Lori Stockert; Pamela Young; Wael Joseph; Rajiv Mundayat; Daniela Graham; Christopher Ritchlin
Journal:  RMD Open       Date:  2021-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.